MA43088B1 - Anticorps anti-il-17c - Google Patents
Anticorps anti-il-17cInfo
- Publication number
- MA43088B1 MA43088B1 MA43088A MA43088A MA43088B1 MA 43088 B1 MA43088 B1 MA 43088B1 MA 43088 A MA43088 A MA 43088A MA 43088 A MA43088 A MA 43088A MA 43088 B1 MA43088 B1 MA 43088B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- relates
- fragments
- psoriasis
- humans
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 102000013691 Interleukin-17 Human genes 0.000 abstract 1
- 108050003558 Interleukin-17 Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne des anticorps ou des fragments d'anticorps se liant à l'il-17c humaine. En particulier, l'invention concerne des anticorps ou des fragments d'anticorps qui présentent des propriétés bénéfiques combinées et sont donc utiles pour le traitement d'êtres humains présentant, par exemple, une dermatite atopique ou un psoriasis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156582 | 2016-02-19 | ||
| EP16156651 | 2016-02-22 | ||
| PCT/EP2017/053592 WO2017140831A1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps anti-il-17c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43088A1 MA43088A1 (fr) | 2019-05-31 |
| MA43088B1 true MA43088B1 (fr) | 2020-10-28 |
Family
ID=58057136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43088A MA43088B1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps anti-il-17c |
| MA44227A MA44227B1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps pour il-17c |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44227A MA44227B1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps pour il-17c |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20190048071A1 (fr) |
| EP (1) | EP3416983B1 (fr) |
| JP (2) | JP6535139B2 (fr) |
| KR (1) | KR20180109977A (fr) |
| CN (1) | CN108699143B (fr) |
| AU (1) | AU2017219837B2 (fr) |
| BR (1) | BR112018016798A2 (fr) |
| CA (1) | CA3014842A1 (fr) |
| CL (1) | CL2018002340A1 (fr) |
| CO (1) | CO2018008724A2 (fr) |
| CU (1) | CU20180087A7 (fr) |
| CY (1) | CY1124296T1 (fr) |
| DK (1) | DK3416983T3 (fr) |
| EA (1) | EA037813B1 (fr) |
| EC (1) | ECSP18070641A (fr) |
| ES (1) | ES2877376T3 (fr) |
| HR (1) | HRP20211059T1 (fr) |
| HU (1) | HUE054755T2 (fr) |
| IL (1) | IL260733B2 (fr) |
| LT (1) | LT3416983T (fr) |
| MA (2) | MA43088B1 (fr) |
| MD (1) | MD3416983T2 (fr) |
| MX (1) | MX2018009860A (fr) |
| PH (1) | PH12018501739A1 (fr) |
| PL (1) | PL3416983T3 (fr) |
| RS (1) | RS62012B1 (fr) |
| SG (1) | SG11201806161TA (fr) |
| SI (1) | SI3416983T1 (fr) |
| TN (1) | TN2018000289A1 (fr) |
| TW (1) | TW201734041A (fr) |
| WO (1) | WO2017140831A1 (fr) |
| ZA (1) | ZA201806249B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43088B1 (fr) * | 2016-02-19 | 2020-10-28 | Morphosys Ag | Anticorps anti-il-17c |
| US20230203149A1 (en) * | 2017-09-25 | 2023-06-29 | Morphosys Ag | Treatment of atopic dermatitis |
| GB201803563D0 (en) | 2018-03-06 | 2018-04-18 | Galapagos Nv | Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases |
| TW202011995A (zh) * | 2018-07-03 | 2020-04-01 | 比利時商葛萊伯格有限公司 | 高濃度液體抗體配製物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| DK1076703T4 (da) * | 1998-05-15 | 2011-03-28 | Genentech Inc | Terapeutiske anvendelser af IL-17-homologe polypeptider |
| DE60041119D1 (de) | 1999-07-20 | 2009-01-29 | Morphosys Ag | Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen |
| WO2003048731A2 (fr) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Categorisation d'anticorps reposant sur des caracteristiques de liaison |
| JP2008516985A (ja) | 2004-10-18 | 2008-05-22 | ザイモジェネティクス，インコーポレイティド | 可溶性ｚｃｙｔｏｒ２１、抗ｚｃｙｔｏｒ２１抗体及び結合パートナー、並びに炎症における使用方法 |
| CA2624763A1 (fr) * | 2005-10-18 | 2007-04-26 | Zymogenetics, Inc. | Antagonistes de il-17c et methodes d'utilisation desdits antagonistes |
| CA2666842A1 (fr) | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Antagonistes de l'il-17c et leurs procedes d'utilisation |
| US20120201821A1 (en) * | 2010-10-25 | 2012-08-09 | Gonzalez Jr Lino | Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma |
| SG189950A1 (en) | 2010-11-19 | 2013-06-28 | Morphosys Ag | A collection and methods for its use |
| WO2013016220A1 (fr) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Récepteur a de il-il-17 requis pour biologie il-17c |
| TR201807056T4 (tr) * | 2011-10-19 | 2018-06-21 | Galapagos Nv | İnflamatuar bozuklukların tedavisine yönelik IL17C antagonistleri. |
| DK2858670T3 (en) | 2012-06-12 | 2018-10-22 | Orega Biotech | Antagonists of IL-17 isoforms and their applications |
| RU2017122172A (ru) * | 2014-12-15 | 2019-01-17 | МорфоСис АГ | Антитела к IL-17C |
| MA43088B1 (fr) * | 2016-02-19 | 2020-10-28 | Morphosys Ag | Anticorps anti-il-17c |
-
2017
- 2017-02-17 MA MA43088A patent/MA43088B1/fr unknown
- 2017-02-17 KR KR1020187024953A patent/KR20180109977A/ko not_active Application Discontinuation
- 2017-02-17 IL IL260733A patent/IL260733B2/en unknown
- 2017-02-17 EA EA201891594A patent/EA037813B1/ru unknown
- 2017-02-17 RS RS20210775A patent/RS62012B1/sr unknown
- 2017-02-17 PL PL17705873T patent/PL3416983T3/pl unknown
- 2017-02-17 US US16/076,401 patent/US20190048071A1/en not_active Abandoned
- 2017-02-17 MA MA44227A patent/MA44227B1/fr unknown
- 2017-02-17 SI SI201730777T patent/SI3416983T1/sl unknown
- 2017-02-17 SG SG11201806161TA patent/SG11201806161TA/en unknown
- 2017-02-17 CN CN201780011965.2A patent/CN108699143B/zh active Active
- 2017-02-17 WO PCT/EP2017/053592 patent/WO2017140831A1/fr active Application Filing
- 2017-02-17 AU AU2017219837A patent/AU2017219837B2/en active Active
- 2017-02-17 EP EP17705873.2A patent/EP3416983B1/fr active Active
- 2017-02-17 MD MDE20190007T patent/MD3416983T2/ro unknown
- 2017-02-17 TN TNP/2018/000289A patent/TN2018000289A1/en unknown
- 2017-02-17 MX MX2018009860A patent/MX2018009860A/es unknown
- 2017-02-17 CU CU2018000087A patent/CU20180087A7/es unknown
- 2017-02-17 DK DK17705873.2T patent/DK3416983T3/da active
- 2017-02-17 BR BR112018016798A patent/BR112018016798A2/pt unknown
- 2017-02-17 JP JP2018543220A patent/JP6535139B2/ja active Active
- 2017-02-17 TW TW106105384A patent/TW201734041A/zh unknown
- 2017-02-17 CA CA3014842A patent/CA3014842A1/fr active Pending
- 2017-02-17 LT LTEP17705873.2T patent/LT3416983T/lt unknown
- 2017-02-17 ES ES17705873T patent/ES2877376T3/es active Active
- 2017-02-17 HU HUE17705873A patent/HUE054755T2/hu unknown
-
2018
- 2018-08-08 US US16/058,143 patent/US10259869B2/en active Active
- 2018-08-16 CL CL2018002340A patent/CL2018002340A1/es unknown
- 2018-08-16 PH PH12018501739A patent/PH12018501739A1/en unknown
- 2018-08-21 CO CONC2018/0008724A patent/CO2018008724A2/es unknown
- 2018-09-17 ZA ZA2018/06249A patent/ZA201806249B/en unknown
- 2018-09-19 EC ECSENADI201870641A patent/ECSP18070641A/es unknown
-
2019
- 2019-02-26 US US16/286,231 patent/US10633439B2/en active Active
- 2019-04-26 JP JP2019086144A patent/JP6916834B2/ja active Active
-
2020
- 2020-03-18 US US16/822,844 patent/US11987621B2/en active Active
-
2021
- 2021-07-02 HR HRP20211059TT patent/HRP20211059T1/hr unknown
- 2021-07-06 CY CY20211100604T patent/CY1124296T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MA43088B1 (fr) | Anticorps anti-il-17c | |
| CA3156451A1 (fr) | Anticorps ayant une specificite pour la nectine -4 et leurs utilisations | |
| MA40476B1 (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
| MA45029B1 (fr) | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer | |
| MY191649A (en) | Antibodies to tigit | |
| EA201792616A1 (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| MX2018014761A (es) | Anticuerpos anti inmunoglobulina e (ige). | |
| MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
| MX2015011959A (es) | Anticuerpos que unen il-23. | |
| MA43717B1 (fr) | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci | |
| UA105384C2 (ru) | Лечение нарушений, связанных с инсулинорезистентностью | |
| WO2022051591A3 (fr) | Anticorps anti-nectine-4 et leurs utilisations | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MX2022008659A (es) | Moléculas de anticuerpos específicos contra c5ar1 y usos de estas. | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| EP4023674A3 (fr) | Anticorps anti-il-22r | |
| MX2021011040A (es) | Anticuerpos dirigidos contra c5ar. | |
| MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. | |
| MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
| MA43600B2 (fr) | Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire | |
| MX2022016591A (es) | Moléculas de anticuerpo contra april y usos de las mismas. | |
| MA49607A1 (fr) | Anticorps monoclonal pour il-5ra | |
| EA202192101A1 (ru) | Соединения и их применение |